123183-72-2

Basic information

• Product Name: tert-butyl methyl(3-(methylamino)propyl)carbamate
• Synonyms: tert-butyl methyl(3-(methylamino)propyl)carbamate
• CAS NO: 123183-72-2
• Molecular Weight: 202.297
• Mol File: 123183-72-2.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: tert-butyl methyl(3-(methylamino)propyl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl methyl(3-(methylamino)propyl)carbamate(123183-72-2)
• EPA Substance Registry System: tert-butyl methyl(3-(methylamino)propyl)carbamate(123183-72-2)

Safety Data

• Hazardous Substances Data: 123183-72-2(Hazardous Substances Data)

Upstream product

• 98642-44-5 tert-butyl (3-hydroxypropyl)methylcarbamate 
• 74-89-5 methylamine 
• 273756-96-0 methanesulfonic acid 2-(tert-butoxycarbonyl-methyl-amino)propyl ester 
• 1111237-72-9 C₁₇H₂₈N₂O₂ 
• 24424-99-5 di-tert-butyl dicarbonate 
• 111-33-1 1,3-bis(methylamino)propane 

Downstream Products

• 1111235-76-7 C₁₇H₂₆ClN₅O₂ 
• 7226-23-5 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
• 1426551-51-0 quinone-trimethyllock-C₃-diamine-Boc 
• 1246248-08-7 1-(2-{[3-(1-{4-[{3-[(tert-butoxycarbonyl)(methyl)amino]propyl}(methyl)carbamoyl]phenyl}piperidin-4-yl)propanoyl](methyl)amino}ethyl)piperidin-4-yl biphenyl-2-ylcarbamate 
• 1246246-97-8 C₄₄H₆₁FN₆O₆ 
• 1246246-95-6 tert-butyl (3-{[(4-amino-2-fluorophenyl)carbonyl](methyl)amino}propyl)methylcarbamate 
• 1246246-96-7 1-{2-[{6-[(3-Fluoro-4-{methyl[3-(methylamino)propyl]carbamoyl}phenyl)amino]hexanoyl}(meth yl)amino]ethyl}piperidin-4-yl biphenyl-2-ylcarbamate 

Relevant articles and documents

A Bioreductive Prodrug of Cucurbitacin B Significantly Inhibits Tumor Growth in the 4T1 Xenograft Mice Model

Cucurbitacin B (CuB), a highly cytotoxic constituent of the Cucurbitaceae plant, was identified to exhibit potent inhibitory activity against human cancer cells as well as normal cells. This disadvantage hampers the possibility of developing this compound into an anticancer drug candidate. In this work, several bioreductive prodrugs of CuB were designed to reduce toxicity to normal cells while maintaining the cytotoxic effect to cancer cells. Embedded with a bioreductive delivery and cleavable system in cancer tissues, cucurbitacin B-based prodrugs 1, 2, and 3 were synthesized and evaluated by in vitro and in vivo experiments. Compared with the parent CuB, prodrug 1 was found to significantly reduce the toxicity down to 310-fold lower against noncancerous cells. LC-MS analyses show that prodrug 1 efficiently releases the parent compound in the reductase-overexpressed MCF-7 cells. In addition, prodrug 1 shows satisfactory and comparable effectiveness in controlling tumor growth as that by tamoxifen in the 4T1 xenograft mice model.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

From Cells to Mice to Target: Characterization of NEU-1053 (SB-443342) and Its Analogues for Treatment of Human African Trypanosomiasis

Human African trypanosomiasis is a neglected tropical disease that is lethal if left untreated. Existing therapeutics have limited efficacy and severe associated toxicities. 2-(2-(((3-((1H-Benzo[d]imidazol-2-yl)amino)propyl)amino)methyl)-4,6-dichloro-1H-indol-1-yl)ethan-1-ol (NEU-1053) has recently been identified from a high-throughput screen of >42,000 compounds as a highly potent and fast-acting trypanocidal agent capable of curing a bloodstream infection of Trypanosoma brucei in mice. We have designed a library of analogues to probe the structure-activity relationship and improve the predicted central nervous system (CNS) exposure of NEU-1053. We report the activity of these inhibitors of T. brucei, the efficacy of NEU-1053 in a murine CNS model of infection, and identification of the target of NEU-1053 via X-ray crystallography.